Background: Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
COVID-19 is an ongoing global outbreak of coronavirus disease 2019, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on January 30, 2020; and a pandemic on March 11, 2020.
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.
Areas of uncertainty:
We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.
- Infection-enhancing antibodies have been detected in symptomatic Covid-19
- Antibody dependent enhancement (ADE) is a potential concern for vaccines
- Enhancing antibodies recognize both the Wuhan strain and Delta variants
- ADE of Delta variants is a potential risk for current vaccines
- Vaccine formulations lacking ADE epitope are suggested
DSA ADS Course - 2021
COVID19, Public Policy, Health Policy, Modeling, Model-driven Science, Empirically-driven Science, Lockdowns, Non-pharmaceutical Interventions, NPIs
Discuss 2 paradigms: Model-driven Science vs. Empirically-driven Science